Excerpts from analyst's report

Maybank Kim Eng analyst: John Cheong

diagnostic imagingSingapore Medical Group (SMG) is a primary and secondary healthcare specialist group with 28 employed doctors and more than 35 associated doctors. It focuses on healthcare, diagnostics, and aesthetics. (Photo: Company)

Initiate SMG at BUY with Target Price of SGD0.59

This under-researched stock focuses on premium specialist healthcare services and is set to undergo high growth from robust expansion of its seven key specialities. It offers:

  1. A scalable asset-light model
  2. Attractive market positioning
  3. Good turnaround track record and high-profile shareholders.

Its renewed growth profile stems from its earnings turnaround in 1H16, as a result of efforts from the new CEO and Tony Tan (founder of Parkway Holdings, a multi-billion dollar healthcare group today), who took over the ailing company in 2013. Despite M&A being a key part of the company’s growth strategy, we forecast nothing in addition to those already completed. One further M&A deal could lift our FY17E EPS & TP by at least 7%.

 

Scalable asset-light model

SMG’s asset-light model allows it to scale up rapidly. Since 2013, the number of doctors has risen 75% to 28. For M&A, SMG has been able to secure synergistic deals. Its successes include:

  1. Acquiring and turning around loss-making medical screening businesses
  2. Acquiring a profitable women’s specialist group made up of senior doctors at 13x P/E with 5-yr profit guarantee.

It aims to add at least SGD1m in earnings via M&A each year and it is also expanding overseas.

♦ M&A key to growth strategy

johncheong maybank9.14LQM 0094FFOne further M&A deal could lift our FY17E EPS & target price by at least 7%.

-- John Cheong (photo)

Attractive market positioning

SMG’s multi-disciplinary platform differentiates it from other listed healthcare players and allows it to tap more growth opportunities.

It attracts young and motivated doctors, as it offers a good cross-referral network.

As the platform grows, SMG will acquire senior doctors that seek to grow their practices, like the recent proposed acquisition of Astra Women’s Specialist Group. It prefers buying practices that are willing to provide mentorship and has a stable patient pool.

Stock price  48c
52-week range 14c - 48.5c
Market cap S$143.1 m
PE ratio 175.2
Price-to-book 11.5
Debt/EBITDA 0.923
Source: StockFacts

Under-researched; M&A potential not yet priced in

Our TP of SGD0.59 is based on 27x FY17E EPS, pegged to the average 2-yr forward P/E mean of small-cap healthcare peers in Singapore (Q&M, ISEC, Singapore O&G).

As SMG’s market recognition increases and it further establishes its growth track record, we believe it could re-rate closer to the market leader, Raffles Medical’s FY17E P/E of 33x.

Valuation cross-check using DCF indicates a TP of SGD0.56. We have not factored in any future M&A, where a SGD1m profit deal could lift EPS by c.7%. Risks are competition, integration risk and regulatory changes.


For full report, click here.

You may also be interested in:


You have no rights to post comments

Counter NameLastChange
AEM Holdings1.9100.090
Best World2.4900.010
Boustead Singapore0.950-
Broadway Ind0.132-
China Aviation Oil (S)0.8700.005
China Sunsine0.395-
ComfortDelGro1.440-0.010
Delfi Limited0.8750.005
Food Empire1.120-0.010
Fortress Minerals0.285-0.015
Geo Energy Res0.3000.010
Hong Leong Finance2.420-
Hongkong Land (USD)3.4500.030
InnoTek0.510-
ISDN Holdings0.3050.005
ISOTeam0.0510.002
IX Biopharma0.038-0.001
KSH Holdings0.250-
Leader Env0.049-
Ley Choon0.0530.003
Marco Polo Marine0.0710.001
Mermaid Maritime0.1560.014
Nordic Group0.305-
Oxley Holdings0.0880.001
REX International0.1280.004
Riverstone0.8850.025
Southern Alliance Mining0.480-
Straco Corp.0.4900.005
Sunpower Group0.2150.010
The Trendlines0.062-0.001
Totm Technologies0.021-
Uni-Asia Group0.8250.005
Wilmar Intl3.2000.020
Yangzijiang Shipbldg1.7600.020
 

We have 1548 guests and no members online

rss_2 NextInsight - Latest News